John Hardy, MD
Psychiatry · Pueblo, CONPI 1619032182
Payments from drug & device makers
Across 1,282 payments — averaging $691.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$579K
- Avanir Pharmaceuticals, Inc.$78K
- E.r. Squibb & Sons, L.L.C.$66K
- AbbVie$42K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$38K
- Eisai Inc.$20K
- plus $64K from 19 others
What the payments were for
- Consulting fees$61,5217%
- Speaking & faculty fees$636,15077%
- Travel & lodging$103,37812%
- Food & beverage$26,9543%
- Education$4130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 733 | $578,737 |
| Avanir Pharmaceuticals, Inc. | 46 | $77,985 |
| E.r. Squibb & Sons, L.L.C. | 110 | $65,916 |
| AbbVie(2 entities) | 89 | $41,576 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 61 | $38,385 |
| Eisai Inc. | 39 | $19,717 |
| Teva Pharmaceuticals USA, Inc. | 39 | $18,171 |
| Alkermes, Inc. | 52 | $13,612 |
| Janssen Scientific Affairs, LLC | 22 | $13,568 |
| Sunovion Pharmaceuticals Inc. | 24 | $12,345 |
| Johnson & Johnson | 15 | $3,463 |
| Pfizer | 1 | $1,625 |
| Otsuka America Pharmaceutical, Inc. | 7 | $277 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $250 |
| Axsome Therapeutics, Inc. | 9 | $226 |
| Vanda Pharmaceuticals Inc. | 4 | $176 |
| Lundbeck LLC | 6 | $139 |
| Acadia Pharmaceuticals Inc | 3 | $139 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $94 |
| Supernus Pharmaceuticals, Inc. | 3 | $45 |
| Idorsia Pharmaceuticals US Inc | 2 | $42 |
| Ironshore Pharmaceuticals Inc. | 2 | $36 |
| Almatica Pharma LLC | 1 | $22 |
| Tris Pharma Inc | 1 | $19 |
| Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$886,580 in reported general payments places this provider in the 95th percentile of 559 psychiatry providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 24 | $192,842 |
| VraylarCariprazine Hcl | 68 | $96,726 |
| TrintellixVortioxetine Hydrobromide | 122 | $85,806 |
| LybalviOlanzapine/Samidorphan Malate | 26 | $40,683 |
| RexultiBrexpiprazole | 25 | $35,825 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $19,519 |
| QuviviqDaridorexant Hcl | 24 | $11,138 |
| Duloxetine Hcl | 265 | $8,003 |
| Lamotrigine | 502 | $6,268 |
| Aripiprazole | 196 | $5,409 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,867 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 168 | $4,793 |
| Olanzapine | 110 | $4,624 |
| Vilazodone Hcl | 26 | $4,029 |
| Modafinil | 28 | $3,902 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $578,737 | $192,84224 claims |
| AbbVieVraylar | $41,576 | $96,72668 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $250 | $90,673134 claims |
| Alkermes, Inc.Lybalvi | $13,612 | $40,68326 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $277 | $35,82525 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $77,985 | $19,51912 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $42 | $11,13824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 559 psychiatry providers in Colorado.
Other psychiatry in Pueblo
- John DequardoPueblo$17K
- Musharraf NizamiPueblo$6K
- Artin TerhakopianPueblo$2K
- Andrew SedilloAurora$3.7M
- David WeissHighlands Ranch$1.1M
- Larry SandersLittleton$779K
- Jeffrey RichmondDenver$424K
- Sara MarkeyDenver$209K
- Jennifer FrenchGlendale$115K
- Cynthia EppersonAurora$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.